Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response Trial
Kris Kowdley(Liver Institute Northwest), Charles A. McWherter(University Health Network), Stephen F. Carroll(IGM Biosciences (United States)), Elisabet Mena(California Liver Research Institute), Alan Bonder(Beth Israel Deaconess Medical Center), Kessendri Reddy(University of Chicago), Franco Frigerio, Kidist Yimam(California Pacific Medical Center), Christophe Corpechot(Inserm), Ke Yang(Northwestern Polytechnical University), Sumit Kumar(Cornell University), Daria B. Crittenden(Gilead Sciences (Canada))
Cited by 2
Related Papers
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518
Crystal Structure of Human BPI and Two Bound Phospholipids at 2.4 Angstrom Resolution
|Science|1997|360
Structure, Function, and Therapeutic Use of IgM Antibodies
|Antibodies|2020|257